Copper Road Announces Upsize to Financing

Copper Road Announces Upsize to Financing GlobeNewswire December 17, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Copper Road Resources Inc. (TSX-V: CRD) (“Copper Road” or the “Company”) announces today that it is amending certain terms of its non-brokered […]

ExGen Signs Binding LOI to Acquire Silver Stream on Past-Producing Gold Mine

ExGen Signs Binding LOI to Acquire Silver Stream on Past-Producing Gold Mine GlobeNewswire December 17, 2025 NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — ExGen Resources Inc. (TSX.V: EXG; OTC: BXXRF) (“ExGen” or the “Company“) is pleased to announce

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference

Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 17, 2025 SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will present at the 44th

Higher Customer Spend: How the Best Hospitality Venues Get It Right with Music and Onscreen Entertainment with Orange Door Music Video Inc.

Higher Customer Spend: How the Best Hospitality Venues Get It Right with Music and Onscreen Entertainment with Orange Door Music Video Inc. Newly released consumer data reinforces what top-performing venues have known for years: when music and digital screens set the mood, customers stay longer, spend more, and come back sooner. GlobeNewswire December 17, 2025

PyroGenesis Signs Contract Toward the Use of Plasma in the Treatment of Low-Level Radioactive Waste

PyroGenesis Signs Contract Toward the Use of Plasma in the Treatment of Low-Level Radioactive Waste Design phase contract is with a European specialist in radioactive waste processing and nuclear decommissioning GlobeNewswire December 17, 2025 MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature

Abaxx Calls Warrants, Provides Corporate Update

Abaxx Calls Warrants, Provides Corporate Update GlobeNewswire December 17, 2025 TORONTO, Dec. 17, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company“), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd., the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing“), and producer

NevGold Adds 6 Square Kilometers of Highly Prospective Outcropping Antimony-Gold Targets at Limo Butte, Nevada

NevGold Adds 6 Square Kilometers of Highly Prospective Outcropping Antimony-Gold Targets at Limo Butte, Nevada GlobeNewswire December 17, 2025 Vancouver, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company“) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that is has staked an additional 90 claims, approximately 6 square kilometers or 1500

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease

4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease GlobeNewswire December 17, 2025 Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference

Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference GlobeNewswire December 17, 2025 ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that the company will be participating

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program GlobeNewswire December 17, 2025 License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applications Collaboration supports Sagimet's fixed-dose combination

Scroll to Top